Drugs /

abbv-744

Back to Drugs List

Overview

NCI Definition [1]:
An orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, the BET inhibitor ABBV-744 preferentially binds to the second bromodomain (BD2) of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of proliferation in BET-overexpressing tumor cells. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that contain two homologous bromodomains, the BD1 and BD2 domains. They play an important role during development and cellular growth.

Clinical Trials

View Clinical Trials for abbv-744

Abbv-744 has been investigated in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials investigating abbv-744, 2 are phase 1 (1 open).

KMT2A Fusion, KMT2A-AFF1 Fusion, and KMT2A-ELL Fusion are the most frequent biomarker inclusion criteria for abbv-744 clinical trials.

Acute myeloid leukemia, myelofibrosis transformation in essential thrombocythemia, and polycythemia vera, post-polycythemic myelofibrosis phase are the most common diseases being investigated in abbv-744 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Abbv-744
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Abbv-744
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating abbv-744 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
abbv 744, abbv744, bd2-selective bet inhibitor abbv-744, bet inhibitor abbv-744
Drug Target(s) [2]:
BRD2, BRD3, BRD4, BRDT
NCIT ID [1]:
C148415

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.